Compare Duke Energy Corp (DUK) vs Novavax Inc (NVAX) Price & Performance

Duke Energy (DUK) trades at $126.86, up 1.1% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows stable revenue growth, with 2025 revenue reaching $32.24B and net income of $4.97B, supported by a 15.49% net margin. Recent news highlights a dividend increase to $1.085 per share and strong institutional interest, with 37.5% of analysts rating it a Buy.

The outlook remains positive with a consensus price target of $136.60, offering ~7.7% upside. Risks include high debt levels (46.17% debt-to-asset ratio) and regulatory pressures, but the company's defensive utility profile and dividend reliability provide stability amid market volatility.

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.